Yuping Shen

Innovent Biologics, Inc.

SCHOLARLY PAPERS

1

DOWNLOADS

45

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study

Number of pages: 27 Posted: 30 Nov 2023
Bin Lian, Juan Li, Lu Si, Zhihong Chi, Lili Mao, Xuan Wang, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Yuping Shen, Qun Guo, Shirui Zheng, Jun Guo and Chuanliang Cui
Beijing Cancer Hospital, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Innovent Biologics, Inc., Innovent Biologics, Inc., Innovent Biologics, Inc., Peking University - Key Laboratory of Carcinogenesis and Translational Research and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 45 (895,370)

Abstract:

Loading...

CTLA-4, IBI310, Combination immunotherapy, Melanoma, Urothelial carcinoma